Elicera Therapeutics to participate in upcoming investor and partnering events

Uppsala, Sweden, October 2 2026 - Elicera Therapeutics AB (publ) today announces that the company will participate in several industry, partnering and investor conferences in Sweden, Europe and the US during the fourth quarter of 2026. At these events, the company will present its business, the latest results from the Phase I part of the CARMA clinical study of the CAR T-cell therapy ELC-301, and its proprietary iTANK platform. Elicera develops next-generation immuno-oncology treatments based on iTANK-armed CAR T cells and oncolytic viruses. The company's CAR T-cell therapy ELC-301 is being evaluated in the Phase I/IIa clinical study CARMA for the treatment of patients with B-cell lymphoma who have no remaining treatment options. The Phase IIa part of the study has been approved by the Swedish Medical Products Agency, and patient recruitment is expected to begin in the fourth quarter of 2026. During the fourth quarter of 2026, Elicera Therapeutics will participate in the following meetings and conferences: Cell & Gene Meeting on the Mesa 2026 October 5-7, Phoenix, USA Partnering meeting for the cell and gene therapy sector, organised by the Alliance for Regenerative Medicine (ARM). https://meetingonthemesa.com Symposium on the Future of Cell and Gene Therapy, hosted by CCRM October 22, Gothenburg, Sweden Elicera's CEO Johan Liwing has been invited to take part in a panel discussion entitled "Bridging the competitiveness gap for ATMPs". BioStock Life Science Summit 2026 November 4-5, Lund, Sweden CEO Johan Liwing will present the company on 4 November at 13:45 CET. https://biostock.se/en/event/life-science-summit-2026/ Advanced Therapies USA 2026 November 4-5, Boston, USA Congress and partnering meeting focused on the development and manufacturing of cell and gene therapies. Chair of the Board Margareth Jorvid will give a presentation on the topic "Effectively interacting with regulatory authorities" and take part in a panel discussion entitled "Navigating the Global Regulatory Landscape". https://www.terrapinn.com/conference/advanced-therapies-usa/ BIO-Europe 2026 November 9-11, Cologne, Germany Europe's largest partnering conference for the pharmaceutical and biotech industries. https://informaconnect.com/bioeurope/ ATMP Sweden 2026 Conference December 1-2, Campus Flemingsberg, Stockholm Nordic conference on advanced therapy medicinal products (ATMPs), bringing together industry, academia and healthcare. https://atmpsweden.se/event/atmp-sweden-2026-conference/ Redeye Life Science Day 2026 December 2, Stockholm CEO Johan Liwing will present the company in the morning. The presentation will be broadcast live on www.redeye.se and will be available on demand afterwards. https://www.redeye.se/events Pharma Outsourcing 2026 December 2, Stockholm CEO Johan Liwing has been invited to give a presentation entitled "Building for the Next Clinical Stage - How a Cell & Gene Therapy Biotech Needs to Evolve". https://nmevents.se/pharmaoutsourcing "Backed by the positive results reported from the Phase I part of the CARMA study, we are entering a period with many opportunities to meet potential partners, investors and other players in the cell and gene therapy field. We look forward to presenting Elicera, ELC-301 and the iTANK platform, and to deepening our dialogue with both industry and the capital markets, in Sweden as well as internationally," says Johan Liwing, CEO of Elicera Therapeutics. For further information please contact: Johan Liwing, CEO, Elicera Therapeutics AB Phone: +46 (0) 706 70 36 75 johan.liwing@elicera.com Certified Advisor DNB Carnegie Investment Bank (publ) [1]: https://meetingonthemesa.com [2]: https://biostock.se/en/event/life-science-summit-2026/ [3]: https://www.terrapinn.com/conference/advanced-therapies-usa/ [4]: https://informaconnect.com/bioeurope/ [5]: https://atmpsweden.se/event/atmp-sweden-2026-conference/ [6]: https://www.redeye.se/events [7]: https://nmevents.se/pharmaoutsourcing [8]: mailto:johan.liwing@elicera.com